Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHELLY SENDERS

Allopathic & Osteopathic Physicians Pediatrics

NPI
1629030242
CMS profile
72774
Location
SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$19.72

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $19.72 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $19.72 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHELLY SENDERS

NPI 1629030242 · CMS profile ID 72774

Allopathic & Osteopathic Physicians / Pediatrics

SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629030242?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $19.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $19.7207/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128731674 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,200.00 1
PY2021 $20.00 1
PY2024 $19.72 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,019.97 12
PY2025 Principal investigator $1,902,218.36 170
PY2024 Recipient $275,103.88 9
PY2024 Principal investigator $1,504,720.66 124
PY2023 Recipient $102,576.00 31
PY2023 Principal investigator $2,132,839.28 106
PY2022 Recipient $295,641.25 8
PY2022 Principal investigator $2,774,710.46 131
PY2021 Recipient $6,400.00 2
PY2021 Principal investigator $3,331,898.39 191
PY2020 Recipient $940.00 1
PY2020 Principal investigator $1,688,992.60 356
PY2019 Principal investigator $803,780.84 320

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

133 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $8,762.56 12/31/2024 Non-covered Recipient Entity
Senders Pediatrics
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1136404476
Principal investigator 1 PFIZER INC. $14,959.29 12/31/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130969689
Principal investigator 1 PFIZER INC. $5,435.10 12/31/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1130971605
Principal investigator 1 PFIZER INC. $2,072.72 12/31/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130971610
Principal investigator 1 PFIZER INC. $8,698.85 12/20/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130968433
Principal investigator 1 PFIZER INC. $920.40 12/20/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1130969001
Principal investigator 1 PFIZER INC. $922.77 12/20/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1130969683
Recipient ModernaTX, Inc. $3,142.62 12/19/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190727
Principal investigator 1 SANOFI US SERVICES INC. $1,009.13 12/18/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730672
Principal investigator 1 ModernaTX, Inc. $22,691.44 12/13/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147185065
Principal investigator 1 PFIZER INC. $25,342.14 12/11/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130968439
Principal investigator 1 PFIZER INC. $3,627.26 12/05/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130968427
Principal investigator 1 SANOFI US SERVICES INC. $2,600.00 12/04/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730674
Principal investigator 1 SANOFI US SERVICES INC. $14,019.57 12/02/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730676
Principal investigator 1 PFIZER INC. $1,227.20 11/26/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1130988005
Principal investigator 1 ModernaTX, Inc. $45,609.39 11/22/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147185063
Principal investigator 1 PFIZER INC. $6,591.17 11/22/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130988162
Principal investigator 1 ModernaTX, Inc. $44,185.44 10/25/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147185061
Principal investigator 1 PFIZER INC. $9,778.86 10/23/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130994023
Principal investigator 1 PFIZER INC. $1,053.00 10/16/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1130994028
Principal investigator 1 PFIZER INC. $3,259.62 10/16/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130994177
Principal investigator 1 PFIZER INC. $9,721.39 10/16/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130994457
Principal investigator 1 PFIZER INC. $2,717.55 10/16/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1130994738
Principal investigator 1 SANOFI US SERVICES INC. $86,333.43 10/16/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730678
Principal investigator 1 PFIZER INC. $3,813.16 10/09/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130993884
Principal investigator 1 PFIZER INC. $5,026.06 10/09/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130994183
Principal investigator 1 GlaxoSmithKline, LLC. $344.02 10/07/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537630
Principal investigator 1 PFIZER INC. $29,601.39 10/05/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130993872
Principal investigator 1 PFIZER INC. $746.20 10/05/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1130994172
Principal investigator 1 PFIZER INC. $1,297.40 10/03/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1130994017
Principal investigator 1 PFIZER INC. $33,152.21 10/03/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130994733
Principal investigator 1 PFIZER INC. $7,539.09 10/02/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130993878
Principal investigator 1 PFIZER INC. $11,617.23 10/01/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130994451
Principal investigator 1 ModernaTX, Inc. $31,189.53 09/25/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147185059
Recipient ModernaTX, Inc. $4,570.15 09/25/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190725
Principal investigator 1 PFIZER INC. $4,388.80 09/25/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131013716
Principal investigator 1 PFIZER INC. $25,065.15 09/19/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1131013729
Recipient ModernaTX, Inc. $24,002.26 09/18/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190723
Principal investigator 1 PFIZER INC. $2,545.40 09/18/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131013132
Principal investigator 1 GlaxoSmithKline, LLC. $662.54 09/11/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537612
Principal investigator 1 PFIZER INC. $3,335.80 09/10/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131013116
Principal investigator 1 PFIZER INC. $1,554.54 09/04/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131013127
Principal investigator 1 PFIZER INC. $1,601.60 09/04/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131013722
Principal investigator 1 PFIZER INC. $3,159.26 08/27/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131029037
Principal investigator 1 ModernaTX, Inc. $51,855.11 08/23/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147185035
Principal investigator 1 PFIZER INC. $13,000.00 08/23/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1131028454
Principal investigator 1 PFIZER INC. $10,181.30 08/23/2024 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131029032
Principal investigator 1 PFIZER INC. $10,298.60 08/16/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131028460
Principal investigator 1 GlaxoSmithKline, LLC. $194.59 08/14/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537620
Principal investigator 1 SANOFI US SERVICES INC. $1,872.00 08/14/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730656
Principal investigator 1 ModernaTX, Inc. $37,826.10 08/07/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147185033
Principal investigator 1 PFIZER INC. $6,519.24 07/31/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131042718
Recipient ModernaTX, Inc. $11,926.44 07/29/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190715
Principal investigator 1 PFIZER INC. $9,907.17 07/27/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131042712
Principal investigator 1 ModernaTX, Inc. $132.48 07/26/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147185071
Principal investigator 1 PFIZER INC. $1,086.54 07/26/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131044367
Principal investigator 1 ModernaTX, Inc. $40.86 07/25/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147185069
Principal investigator 1 PFIZER INC. $746.20 07/25/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131042822
Recipient Novavax Inc $9,874.00 07/23/2024 Covered Recipient Physician A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years with a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123373928
Principal investigator 1 ModernaTX, Inc. $17,865.83 07/19/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147185003
Principal investigator 1 SANOFI US SERVICES INC. $53,852.76 07/19/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730646
Principal investigator 1 PFIZER INC. $1,706.40 07/18/2024 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1130917523
Principal investigator 1 GlaxoSmithKline, LLC. $848.87 07/12/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537698
Principal investigator 1 PFIZER INC. $44,414.89 07/11/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131042706
Principal investigator 1 PFIZER INC. $4,196.40 07/11/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131042811
Principal investigator 1 PFIZER INC. $39,804.70 07/06/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131044468
Principal investigator 1 PFIZER INC. $1,279.80 07/03/2024 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1130917723
Principal investigator 1 PFIZER INC. $5,103.80 07/03/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131042817
Principal investigator 1 PFIZER INC. $24,174.80 06/29/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131069974
Recipient ModernaTX, Inc. $122,225.62 06/27/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190721
Principal investigator 1 ModernaTX, Inc. $39,172.96 06/26/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184805
Principal investigator 1 GlaxoSmithKline, LLC. $351.48 06/14/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127537614
Principal investigator 1 GlaxoSmithKline, LLC. $2,614.08 06/14/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537628
Principal investigator 1 PFIZER INC. $1,705.00 06/13/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131068978
Principal investigator 1 PFIZER INC. $11,290.56 06/11/2024 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131067086
Principal investigator 1 PFIZER INC. $19,390.80 06/08/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131065881
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 06/03/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730638
Principal investigator 1 PFIZER INC. $10,602.80 05/29/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131081815
Principal investigator 1 ModernaTX, Inc. $35,314.03 05/24/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184791
Principal investigator 1 GlaxoSmithKline, LLC. $207.75 05/17/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127521928
Principal investigator 1 GlaxoSmithKline, LLC. $217.20 05/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127521930
Principal investigator 1 GlaxoSmithKline, LLC. $830.07 05/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127521932
Principal investigator 1 GlaxoSmithKline, LLC. $1,051.37 05/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537618
Principal investigator 1 GlaxoSmithKline, LLC. $217.20 05/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537624
Principal investigator 1 GlaxoSmithKline, LLC. $217.20 05/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537634
Principal investigator 1 GlaxoSmithKline, LLC. $1,381.88 05/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537700
Principal investigator 1 GlaxoSmithKline, LLC. $1,051.37 05/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537704
Principal investigator 1 SANOFI US SERVICES INC. $6,704.10 05/10/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730634
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 05/08/2024 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730632
Principal investigator 1 GlaxoSmithKline, LLC. $181.66 05/06/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127537710
Principal investigator 1 PFIZER INC. $11,665.96 05/04/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1131081556
Principal investigator 1 PFIZER INC. $17,854.20 05/04/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131081910
Principal investigator 1 ModernaTX, Inc. $3.20 05/03/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184795
Principal investigator 1 ModernaTX, Inc. $2,470.00 05/01/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184797
Principal investigator 1 ModernaTX, Inc. $195.00 04/26/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184767
Principal investigator 1 PFIZER INC. $68,117.76 04/26/2024 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131088571
Principal investigator 1 PFIZER INC. $85.00 04/26/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1131089154
Principal investigator 1 GlaxoSmithKline, LLC. $11,482.00 04/25/2024 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127537608
Principal investigator 1 ModernaTX, Inc. $43,970.94 04/24/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184765
Principal investigator 1 PFIZER INC. $1,580.00 04/19/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131088721
Principal investigator 1 PFIZER INC. $3,412.80 04/18/2024 Non-covered Recipient Entity
Senders PediatricsResearch
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130900389
Principal investigator 1 GlaxoSmithKline, LLC. $12,320.83 04/15/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537702
Principal investigator 1 PFIZER INC. $2,419.20 04/12/2024 Non-covered Recipient Entity
Senders PediatricsResearch
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1130919056
Principal investigator 1 PFIZER INC. $5,760.00 04/09/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1131089160
Principal investigator 1 PFIZER INC. $1,359.80 04/09/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131089947
Principal investigator 1 GlaxoSmithKline, LLC. $541.10 04/08/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127521926
Principal investigator 1 GlaxoSmithKline, LLC. $730.29 04/05/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127537626
Principal investigator 1 PFIZER INC. $38,904.08 04/04/2024 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131088989
Principal investigator 1 PFIZER INC. $11,293.10 04/04/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131089375
Principal investigator 1 ModernaTX, Inc. $49,166.91 04/03/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184769
Principal investigator 1 PFIZER INC. $30,900.00 03/30/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131102960
Recipient ModernaTX, Inc. $52,454.61 03/28/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190719
Principal investigator 1 PFIZER INC. $16,985.54 03/27/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131102998
Principal investigator 1 PFIZER INC. $2,292.48 03/22/2024 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131103004
Principal investigator 1 Merck Sharp & Dohme LLC $6,550.00 03/20/2024 Non-covered Recipient Entity
Senders Pediatrics
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1136404472
Principal investigator 1 GlaxoSmithKline, LLC. $9,103.66 03/15/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537616
Principal investigator 1 PFIZER INC. $746.20 03/08/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131103046
Principal investigator 1 ModernaTX, Inc. $45,071.91 03/06/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184761
Principal investigator 1 PFIZER INC. $8,809.06 03/05/2024 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131102967
Principal investigator 1 PFIZER INC. $3,955.90 03/01/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131103010
Recipient ModernaTX, Inc. $13,500.00 02/29/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190717
Principal investigator 1 GlaxoSmithKline, LLC. $4,561.31 02/09/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537706
Principal investigator 1 GlaxoSmithKline, LLC. $1,423.89 02/08/2024 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127537610
Principal investigator 1 GlaxoSmithKline, LLC. $2,670.27 02/07/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127537632
Principal investigator 1 ModernaTX, Inc. $80,065.44 02/02/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184711
Principal investigator 1 PFIZER INC. $7,976.96 01/31/2024 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131109179
Principal investigator 1 PFIZER INC. $9,107.80 01/26/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1131107231
Principal investigator 1 PFIZER INC. $6,877.44 01/26/2024 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131107709
Recipient ModernaTX, Inc. $33,408.18 01/24/2024 Covered Recipient Physician A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147190713
Principal investigator 1 GlaxoSmithKline, LLC. $4,590.91 01/17/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127537622
Principal investigator 1 GlaxoSmithKline, LLC. $7,646.18 01/10/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127537708
Principal investigator 1 ModernaTX, Inc. $132.48 01/09/2024 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147185067
Principal investigator 1 PFIZER INC. $333.45 01/04/2024 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1131110147